CHU de Tours - Hopital Bretonneau
- Address
- 2 boulevard Tonnellé, 37044 Tours, France
Cardiovascular Research
At CHU de Tours - Hopital Bretonneau, the Neurology department is involved in clinical research on cardiovascular diseases, with a focus on acute ischemic stroke and high-risk transient ischemic attack. These studies are designed to assess whether new treatment approaches can help reduce the risk of recurrent events and improve protection after a cerebrovascular emergency.
- Testing a new therapy aimed at lowering the chance of another ischemic stroke
- Evaluating treatment effectiveness after transient ischemic attack
- Studying prevention strategies for serious neurologic and vascular complications
This work reflects an active interest in improving outcomes for patients facing urgent cerebrovascular conditions.
Hematology and Amyloidosis Studies
The site is also contributing to research in hemic and lymphatic diseases, especially light chain (AL) amyloidosis and advanced hematologic malignancies. The trials are focused on testing new therapies and evaluating how well they may support survival and long-term disease control in people with serious blood-related disorders.
- Assessing a treatment approach for AL amyloidosis in patients with advanced disease
- Exploring safety and effectiveness in hematologic malignancies
- Supporting research into better options for difficult-to-treat blood cancers
These studies aim to improve both symptom management and overall outcomes in complex hematologic conditions.
Oncology and Blood Disease Innovation
Clinical research at CHU de Tours - Hopital Bretonneau also extends into neoplasms, with trials examining new treatment strategies for advanced hematologic malignancies. The main goal is to evaluate whether emerging therapies can offer better disease control and safety for patients with hard-to-treat cancers.
- Investigating a novel therapy for advanced blood-related cancers
- Assessing whether treatment can improve cancer control and patient outcomes
- Expanding therapeutic options in oncology and hematology
This research supports the development of more effective approaches for patients with serious neoplastic diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU de Tours - Hopital Bretonneau
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-08-04 | 2023-08-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.